ov
510(k) Submission ars koi3 “Cf “2
Expansion of NLite Claims a
510(k) Summary Statement
ICN Photonics NLite System JAN 17 2002
1. General Information
Submitter: | ICN Photonics Ltd
Units 1&2 Heol Rhosyn .
Dafen Parc
Llanelli, Carmarthenshire
Wales, UK, SA14 8QG
Contact Person: Dr Mike Kiernan — Director of Clinical Research
Summary Preparation Date: October 17" 2001
2. Names
Device Name: NLite System
Primary Classification Name: Laser Powered Surgical Instrument
3. Predicate Devices
e ICN Photonics Ltd NLite System, cleared August 2000, 510(k) approval
number K000811.
4. Product Description
The NLite System is a flashlamp pumped, pulsed dye laser consisting of the following:
e Main laser console incorporating the laser resonator and external optics, high
voltage delivery system, internal cooler, fluid circulation system, control unit and
user interface;
e Flexible fibre optic delivery device and optical handpiece;
e Footswitch for pulsing control.
5. Indications for Use
The NLite system is indicated for use in the specialties of Dermatology and Plastic
Surgery, and in particular for the treatment of wrinkles.
Page 19 of 20

kK oszyver 772

510(k) Submission A
Expansion of NLite Claims ”
6. Rationale for Substantial Equivalence
The laser system described in this submission is cleared for marketing under 510(k)
approval K000811, August 2000. No modifications to the laser system have been
undertaken.
7. Safety and Efficacy Information
Clinical data has been provided to demonstrate that the NLite system is safe and effective
for the described indications for use.
8. Conclusion
The NLite system has been found to be substantially equivalent to the predicate devices,
specifically in technological design and operation and similar in nature to the desired
physiological interactions. The design and manufacture of the device is in accordance
with the relative international standards and the potential risk to operator and patient have
been minimized.
The clinical data provided has demonstrated that the specific indications for use is met
and the safety and efficacy of the system has been proved.

Page 20 of 20

pr tentey
f , & DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
B
an TT
Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850
Dr. Michael Kiernan
Director of Clinical Research JAN 1 7 2002
ICN Photonics, Ltd.
Units 1 & 2 Heol Rhosyn
Dafen Parc
Llanelli, Carmarthenshire
SA14 8QG
Wales, UK
Re: K013461
Trade/Device Name: Nlite System
Regulation Number: 878.4810
Regulation Name: Laser surgical instrument for use in general and
plastic surgery and in dermatology
Regulatory Class: II
Product Code: GEX
Dated: October 17, 2001
Received: October 18, 2001
Dear Dr. Kiernan:
We have reviewed your Section 510(k) premarket notification of intent to market the device
. referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 — Dr. Michael Kiernan
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and
additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of
Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of
your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the
regulation entitled, "Misbranding by reference to premarket notification” (21CFR Part 807.97).
Other general information on your responsibilities under the Act may be obtained from the
Division of Small Manufacturers, International and Consumer Assistance at its toll-free number
(800) 638-2041 or (301) 443-6597 or at its Internet address
http://www. fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

f Celia M. Witten, Ph.D., M.D.
Director :
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Submission Bair
Expansion of NLite Claims ; ee
Indications for Use Statement as Requested by FDA
510(k) Number (if known): Netknown KO 3 YC/
Device Name: NLite System
Indications for Use:
The NLite System is indicated for use in Dermatological and Plastic Surgery applications
and this device is intended for use in the treatment of wrinkles.
(PLEASE DO NOT WRITE BELOW THIS LINE — CONTINUE ON ANOTHER PAGE IF NEEDED)
“Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)

Division of General, Restorative

and Neurological Devices

510(k) Number__ KO! 3 46/
Prescription Use X OR Over-The-Counter Use
(Per 21 CFR 801.109)

Page 5 of 20

